ArticleAlzheimer's research & therapy2023
Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment.
Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- Aptamer-Based Platforms for Human Aging Biomarkers: Multiplexed Proteomics, Biosensors and Translational Perspectives.International journal of molecular sciences · 2026Review
- Molecular and statistical weaknesses of the p-tau217/AβJournal of molecular medicine (Berlin, Germany) · 2026Review
- Circulating Sphingomyelins Correlate With Plasma T-Tau in Cognitively Unimpaired Older Adults at Risk of Developing Alzheimer's Disease.Journal of neurochemistry · 2026Article
- Impact of cardiometabolic factors and AD plasma biomarkers on white matter hyperintensities volume in individuals with cognitive complaints from the global south.Neuroscience · 2026Article
- Association of Fractional Anisotropy in White Matter Bundles with Plasma Biomarkers of Neurodegeneration and Glial Reactivity in Individuals with Cognitive Complaints without dementia.Research square · 2026Article
- Association between neurodegenerative plasma biomarkers and geriatric depression in older adults with and without clinical dementia in Kinshasa, Democratic Republic of the Congo.Frontiers in psychiatry · 2026Article
- Translating blood-based biomarkers into Alzheimer's disease clinical practice: screening, diagnosis, and longitudinal monitoring.Frontiers in aging neuroscience · 2026Review
- Alzheimer's disease plasma biomarkers are associated with cognitive performance among Hispanic/Latino adults.Communications medicine · 2025Article
- Associations of Plasma p-tau181 With Age, Adjusted for Kidney Function and Sociodemographic Factors.International journal of geriatric psychiatry · 2025Article
- Plasma and MRI biomarkers capture neuronal damage in former professional boxers.Scientific reports · 2025Article
- Diagnostic and discriminative accuracy of plasma phosphorylated tau 217 for symptomatic Alzheimer's disease in a Chinese cohort.The journal of prevention of Alzheimer's disease · 2025Article
- Alterations in CNS-derived blood biomarkers during 30 days simulated microgravity.Frontiers in physiology · 2025Article
- Plasma biomarkers for diagnosis and differentiation and their cognitive correlations in patients with Alzheimer's disease.Brain communications · 2025Article
- Heritability of Alzheimer's disease plasma biomarkers: A nuclear twin family design.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Biofluid biomarkers for Alzheimer's disease: past, present, and future.Medical review (2021) · 2024Review
- Article
- Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessment.Frontiers in neurology · 2024Article
- Preliminary reference values for Alzheimer's disease plasma biomarkers in Congolese individuals with and without dementia.Frontiers in aging neuroscience · 2024Article
- Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessment.medRxiv : the preprint server for health sciences · 2023Article
- Brain-derived neurotrophic factor gene polymorphism affects cognitive function and neurofilament light chain level in patients with subcortical ischaemic vascular dementia.Frontiers in aging neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlasma amyloid-β (Aβ) peptides and tau proteins are promising biomarkers of Alzheimer's disease (AD), not only for predicting Aβ and tau pathology but also for differentiating AD from other neurodegenerative diseases. However, reference intervals for plasma biomarkers of AD in healthy elderly Chinese individuals have not yet been established.
methodsBiomarkers of AD were measured using single-molecule array (Simoa) assays in plasma samples from 193 healthy, cognitively unimpaired Chinese individuals aged 50-89 years. The 95% reference intervals for plasma Aβ42, Aβ40, t-tau, p-tau181, and derived ratios were calculated by using log-transformed parametric methods.
resultsPlasma Aβ42, Aβ40, and p-tau181 levels were positively correlated with age, while the Aβ42/Aβ40 ratio was negatively correlated with age. The 95% reference intervals for plasma Aβ42 and Aβ40 were 2.72-11.09 pg/mL and 61.4-303.9 pg/mL, respectively, and the 95% reference intervals for plasma t-tau and p-tau181 were 0.20-3.12 pg/mL and 0.49-3.29 pg/mL, respectively. The 95% reference intervals for the Aβ42/Aβ40 ratio, p-tau181/t-tau ratio, and p-tau181/Aβ42 ratio were 0.022-0.064, 0.38-6.34, and 0.05-0.55, respectively.
conclusionReference intervals for plasma biomarkers of AD may assist clinicians in making accurate clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.